Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
Tim A LabeurSarah BerhaneJulien EdelineJean-Frederic BlancDominic BettingerTim MeyerJeroen L A Van VugtDavid W G Ten CateRobert A De ManFerry A L M EskensAlessandro CucchettiLaura Jayne BonnettOtto M van DeldenHeinz-Josef KlümpenR Bart TakkenbergPhilip J JohnsonPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
In HCC patients treated with sorafenib, individualized prediction of survival and risk group stratification using baseline prognostic and predictive parameters with the PROSASH model was validated. The refined PROSASH-II model performed at least as good with fewer and more objective parameters. PROSASH-II can be used as a tool for tailored treatment of HCC in daily practice and to define pre-planned subgroups for future studies.